# 'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/hematologyoncology/othercancers/123989) · 2026-11-20 · Medicine
Page: https://themorning.science/story/grand-slam-pancreatic-cancer-drug-shows-promise-as-first-line-treatment-f4386c7b3a05564b
Kind: research · Impact: medium

## In brief

- The first-in-class RAS inhibitor daraxonrasib (Rasonque), combined with chemotherapy, showed promise as a first-line treatment for metastatic pancreatic adenocarcinoma (PDAC).
- The reported results come from an early-stage study.
- Source coverage is a short excerpt, so trial size, endpoints and safety data are not available here.

## Why it matters

If later trials confirm these early results, a RAS inhibitor combined with chemotherapy could become a new first-line option for metastatic pancreatic cancer, a disease with limited treatment choices.

## Coverage

- ['Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment](https://www.medpagetoday.com/hematologyoncology/othercancers/123989) — MedPageToday.com - medical news for physicians, 2026-11-20

Tags: pancreatic cancer, oncology, ras inhibitor, clinical trial, daraxonrasib

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
